Hospital
Sentara Hospitals
Sentara Hospitals was paid $79.69M by Medicaid between Jan 2018 and Dec 2024, across 388 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoSENTARA HOSPITALS
NORFOLK, VA 23502
NORFOLK, VA 23502
33aNPI1811957681assigned 03/24/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$79.69M
24GClaims2,277,166
24DCodes billed388
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#6 of 80
Median peer was paid$14.69M
This provider vs. median5.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HANCOCK, MELINDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 167,804 | $3.22M | |
| 2019 | 271,247 | $6.30M | |
| 2020 | 266,700 | $10.55M | |
| 2021 | 357,921 | $12.64M | |
| 2022 | 416,689 | $14.94M | |
| 2023 | 501,822 | $20.15M | |
| 2024incomplete | 294,983 | $11.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 79,000 | 65,472 | $12.60M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 66,289 | 53,245 | $10.57M |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 33,002 | 23,795 | $9.17M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.4% | 40,086 | 32,608 | $6.71M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.1% | 22,482 | 18,924 | $3.26M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 16,983 | 14,620 | $3.04M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.5% | 57,835 | 14,601 | $2.79M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 16,534 | 13,888 | $2.65M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.9% | 18,172 | 4,843 | $2.31M |
| G0378 | Hospital observation service, per hour | 2.3% | 7,587 | 5,757 | $1.80M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.9% | 1,763 | 1,604 | $1.49M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.8% | 6,055 | 5,289 | $1.42M |
376 more codes
| 59025 | Fetal non-stress test | 1.5% | 6,057 | $1.16M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 24,858 | $1.12M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 5,691 | $904K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 8,220 | $858K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 3,341 | $811K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,330 | $766K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,375 | $711K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13,404 | $670K |
| 97161 | <1% | 6,608 | $566K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,948 | $511K |
| J3490 | Unclassified drugs | <1% | 330,919 | $501K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,996 | $435K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,388 | $392K |
| 58661 | <1% | 123 | $379K | |
| 76642 | <1% | 3,782 | $364K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,211 | $336K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,689 | $320K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 93,595 | $317K |
| 97162 | <1% | 3,135 | $302K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,679 | $295K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 531 | $284K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 21,490 | $265K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 10,767 | $244K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 17,421 | $243K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,251 | $242K |
| 70491 | <1% | 1,277 | $226K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 37,745 | $220K |
| 97597 | <1% | 4,386 | $216K | |
| 93971 | <1% | 2,972 | $216K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,155 | $215K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,420 | $215K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 227 | $197K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,335 | $194K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,312 | $190K |
| 0240U | <1% | 3,475 | $188K | |
| 10060 | <1% | 1,651 | $182K | |
| 76801 | <1% | 4,126 | $174K | |
| 71250 | <1% | 3,011 | $169K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,220 | $166K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 648 | $162K |
| 97598 | <1% | 357 | $158K | |
| 76770 | <1% | 1,495 | $150K | |
| 93970 | <1% | 1,501 | $145K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 572 | $140K |
| 97116 | <1% | 4,444 | $139K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,520 | $135K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 57,227 | $127K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,339 | $120K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14,237 | $120K |
| 97165 | <1% | 1,972 | $117K | |
| 93017 | <1% | 1,793 | $116K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,863 | $114K |
| 93976 | <1% | 2,575 | $113K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 855 | $111K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 468 | $109K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 115 | $107K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 591 | $103K |
| 70496 | <1% | 537 | $102K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 4,129 | $101K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,469 | $99K |
| 59050 | <1% | 668 | $98K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,312 | $89K |
| 83880 | <1% | 11,707 | $86K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,957 | $82K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,155 | $81K |
| 76536 | <1% | 859 | $81K | |
| 97016 | <1% | 2,983 | $80K | |
| 72141 | <1% | 420 | $78K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 281 | $75K |
| 12001 | <1% | 349 | $74K | |
| 80047 | <1% | 21,502 | $72K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,392 | $68K |
| 77065 | Tomosynthesis, mammo | <1% | 2,069 | $68K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 789 | $66K |
| 77066 | Tomosynthesis, mammo | <1% | 2,178 | $65K |
| 70486 | <1% | 1,376 | $65K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 98,426 | $63K |
| 36430 | <1% | 467 | $61K | |
| 82962 | <1% | 32,891 | $54K | |
| 70498 | <1% | 521 | $52K | |
| 74178 | <1% | 234 | $52K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 86 | $51K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 50,285 | $48K |
| 85379 | <1% | 11,232 | $48K | |
| 97760 | <1% | 1,188 | $47K | |
| 71045 | Radiologic examination, chest; single view | <1% | 15,670 | $45K |
| 80076 | <1% | 29,613 | $44K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 5,744 | $42K |
| 80053 | Comprehensive metabolic panel | <1% | 8,713 | $39K |
| 76942 | <1% | 920 | $39K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,542 | $38K |
| 84484 | <1% | 38,580 | $37K | |
| 64415 | <1% | 203 | $36K | |
| 90715 | <1% | 2,262 | $36K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 9,881 | $35K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 35,167 | $34K |
| 97750 | <1% | 1,203 | $34K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,709 | $33K |
| 94060 | <1% | 700 | $33K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 587 | $32K |
| 72110 | <1% | 2,420 | $32K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 252 | $29K |
| 71271 | <1% | 302 | $29K | |
| 84703 | <1% | 20,156 | $28K | |
| 58558 | <1% | 15 | $28K | |
| 94726 | <1% | 988 | $26K | |
| 85027 | <1% | 14,288 | $26K | |
| 94729 | <1% | 1,198 | $25K | |
| 87040 | <1% | 5,737 | $25K | |
| 97113 | <1% | 516 | $24K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 323 | $24K |
| 73630 | <1% | 5,699 | $24K | |
| 73030 | <1% | 3,955 | $23K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,705 | $23K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,724 | $23K |
| 73564 | <1% | 4,601 | $23K | |
| 77080 | <1% | 408 | $21K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,333 | $21K |
| 96376 | <1% | 17,515 | $21K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,834 | $20K |
| 97166 | <1% | 191 | $20K | |
| 12002 | <1% | 145 | $19K | |
| 88307 | <1% | 1,139 | $19K | |
| C1729 | Catheter, drainage | <1% | 3,012 | $17K |
| 73130 | <1% | 3,427 | $17K | |
| 73502 | <1% | 2,483 | $17K | |
| 49083 | <1% | 24 | $17K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,276 | $16K |
| 29581 | <1% | 119 | $16K | |
| 74183 | <1% | 55 | $15K | |
| 76870 | <1% | 211 | $15K | |
| 85610 | <1% | 9,627 | $15K | |
| 72050 | <1% | 701 | $14K | |
| 73562 | <1% | 1,431 | $14K | |
| 73610 | <1% | 3,754 | $13K | |
| 29125 | <1% | 112 | $12K | |
| 81001 | <1% | 48,100 | $12K | |
| 12011 | <1% | 75 | $12K | |
| 72100 | <1% | 952 | $12K | |
| 94799 | <1% | 4,135 | $12K | |
| 92610 | <1% | 153 | $11K | |
| 74174 | <1% | 120 | $11K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 35,021 | $11K |
| 74018 | <1% | 1,537 | $11K | |
| 73221 | <1% | 63 | $11K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,872 | $10K |
| 84702 | <1% | 6,480 | $10K | |
| 94660 | <1% | 46 | $10K | |
| 81003 | <1% | 18,929 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,411 | $9K |
| 86850 | <1% | 4,220 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14,113 | $9K |
| 81025 | <1% | 21,116 | $9K | |
| 97014 | <1% | 453 | $9K | |
| 83605 | <1% | 10,073 | $9K | |
| 86923 | <1% | 411 | $9K | |
| 93880 | <1% | 109 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,073 | $8K |
| 85014 | <1% | 11,980 | $8K | |
| 80061 | Lipid panel | <1% | 2,401 | $7K |
| 97163 | <1% | 165 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,660 | $7K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 30,356 | $7K |
| 85018 | <1% | 2,888 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,711 | $7K |
| 73110 | <1% | 1,667 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 605 | $6K |
| 82565 | <1% | 4,524 | $6K | |
| 83735 | <1% | 9,165 | $6K | |
| 80320 | <1% | 1,525 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,790 | $6K |
| 73700 | <1% | 70 | $6K | |
| 70544 | <1% | 17 | $6K | |
| 99234 | <1% | 611 | $6K | |
| 83690 | <1% | 25,629 | $5K | |
| G0151 | Services performed by a qualified physical therapist in the home health or hospice setting, each 15 minutes | <1% | 140 | $5K |
| 86900 | <1% | 6,335 | $5K | |
| 93350 | <1% | 33 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14,284 | $5K |
| 80143 | <1% | 1,021 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 11,964 | $5K |
| 87077 | <1% | 7,429 | $5K | |
| 82553 | <1% | 1,328 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 11,963 | $4K |
| 87070 | <1% | 1,519 | $4K | |
| 84100 | <1% | 2,937 | $4K | |
| G0152 | Services performed by a qualified occupational therapist in the home health or hospice setting, each 15 minutes | <1% | 159 | $4K |
| 20610 | <1% | 147 | $4K | |
| 36000 | <1% | 53 | $4K | |
| 87186 | <1% | 5,118 | $4K | |
| 96367 | <1% | 412 | $4K | |
| 86901 | <1% | 6,333 | $4K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 180 | $4K |
| 73080 | <1% | 887 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,810 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,487 | $3K |
| 73140 | <1% | 956 | $3K | |
| 93296 | <1% | 544 | $3K | |
| 82077 | <1% | 8,146 | $3K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,173 | $3K |
| 43235 | <1% | 16 | $3K | |
| 77062 | <1% | 79 | $3K | |
| 85730 | <1% | 4,655 | $3K | |
| 73590 | <1% | 969 | $3K | |
| 87210 | <1% | 11,646 | $3K | |
| 97542 | <1% | 105 | $2K | |
| 72131 | <1% | 54 | $2K | |
| 72158 | <1% | 12 | $2K | |
| 97035 | <1% | 33 | $2K | |
| 84145 | <1% | 386 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,982 | $2K |
| 80179 | <1% | 936 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,034 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,339 | $2K |
| 92526 | <1% | 83 | $2K | |
| 94618 | <1% | 28 | $2K | |
| 90686 | <1% | 147 | $2K | |
| 77061 | <1% | 69 | $2K | |
| 76882 | <1% | 19 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,140 | $2K |
| 82607 | <1% | 467 | $2K | |
| 82550 | <1% | 1,945 | $2K | |
| 11721 | <1% | 273 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,708 | $1K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,257 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,299 | $1K |
| 0225U | <1% | 18 | $1K | |
| 97032 | <1% | 24 | $1K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $1K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 4,171 | $1K |
| 72040 | <1% | 56 | $1K | |
| 87081 | <1% | 3,249 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,000 | $1K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 925 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,869 | $1K |
| 85652 | <1% | 1,028 | $997.35 | |
| 51798 | <1% | 144 | $956.07 | |
| 82803 | <1% | 1,927 | $938.28 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,348 | $854.73 |
| C1769 | Guide wire | <1% | 1,198 | $848.52 |
| 73560 | <1% | 94 | $821.37 | |
| 72072 | <1% | 56 | $814.98 | |
| 87631 | <1% | 37 | $635.33 | |
| 85384 | <1% | 599 | $618.86 | |
| 87205 | <1% | 1,557 | $615.90 | |
| 90656 | <1% | 32 | $601.25 | |
| 73552 | <1% | 136 | $594.54 | |
| 96368 | <1% | 41 | $565.06 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 608 | $556.25 |
| 87634 | <1% | 28 | $542.68 | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,897 | $540.94 |
| 84439 | <1% | 154 | $540.26 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 5,551 | $535.64 |
| 36600 | <1% | 256 | $533.67 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,552 | $527.99 |
| 83615 | <1% | 1,116 | $504.23 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,199 | $490.71 |
| 71101 | <1% | 110 | $480.31 | |
| 82310 | <1% | 4,119 | $473.12 | |
| 74022 | <1% | 117 | $434.77 | |
| 82570 | <1% | 823 | $412.52 | |
| 80069 | <1% | 63 | $411.28 | |
| 80164 | <1% | 75 | $410.55 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 698 | $400.26 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,766 | $384.23 |
| 86140 | <1% | 247 | $362.79 | |
| 0115U | <1% | 13 | $361.34 | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 28 | $350.50 |
| 94010 | <1% | 15 | $346.48 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 3,000 | $281.24 |
| 88342 | <1% | 653 | $278.22 | |
| 83970 | <1% | 36 | $275.69 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,019 | $257.89 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,772 | $257.02 |
| 73660 | <1% | 82 | $255.90 | |
| 82746 | <1% | 104 | $255.90 | |
| 84520 | <1% | 717 | $241.40 | |
| 84550 | <1% | 988 | $233.49 | |
| 92611 | <1% | 16 | $231.59 | |
| 74230 | <1% | 16 | $203.92 | |
| 80329 | <1% | 18 | $201.92 | |
| 84156 | <1% | 644 | $190.30 | |
| 82140 | <1% | 192 | $176.20 | |
| 72170 | <1% | 29 | $164.44 | |
| 82728 | <1% | 50 | $162.75 | |
| 83550 | <1% | 170 | $162.72 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,655 | $161.43 |
| 83540 | <1% | 207 | $150.91 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 261 | $150.54 |
| 73090 | <1% | 243 | $143.62 | |
| 82272 | <1% | 1,278 | $141.98 | |
| 82330 | <1% | 400 | $132.76 | |
| 70355 | <1% | 17 | $127.66 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,795 | $112.65 |
| 88304 | <1% | 836 | $109.19 | |
| 88302 | <1% | 72 | $93.36 | |
| 84132 | <1% | 489 | $79.87 | |
| 87340 | <1% | 164 | $61.88 | |
| G0008 | Administration of influenza virus vaccine | <1% | 176 | $46.16 |
| 85045 | <1% | 354 | $45.23 | |
| 84450 | <1% | 277 | $44.24 | |
| 84460 | <1% | 232 | $29.60 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 15 | $29.42 |
| J1815 | Injection, insulin, per 5 units | <1% | 211 | $29.22 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 509 | $25.72 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,280 | $24.68 |
| A6457 | Tubular dressing with or without elastic, any width, per linear yard | <1% | 1,473 | $19.39 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 552 | $17.50 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 133 | $15.33 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 641 | $14.83 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 969 | $14.52 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 99 | $12.91 |
| 85046 | <1% | 480 | $12.78 | |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 459 | $11.89 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,801 | $7.25 |
| 82009 | <1% | 450 | $5.36 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 109 | $4.25 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 198 | $4.12 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 957 | $3.07 |
| 90756 | <1% | 23 | $2.47 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 402 | $2.39 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 17 | $1.75 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 439 | $1.63 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 481 | $1.06 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 714 | $1.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 599 | $0.99 |
| A6252 | Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 922 | $0.97 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 20 | $0.66 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 299 | $0.66 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | <1% | 418 | $0.06 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 376 | $0.01 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 431 | $0.01 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 692 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 213 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 287 | $0.00 |
| 51702 | 0% | 29 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 210 | $0.00 |
| C1782 | Morcellator | 0% | 17 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 361 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 351 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 14 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 122 | $0.00 |
| A6198 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 48 sq. in., each dressing | 0% | 117 | $0.00 |
| 76376 | 0% | 15 | $0.00 | |
| 87075 | 0% | 84 | $0.00 | |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 86 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 25 | $0.00 |
| A6253 | Specialty absorptive dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing | 0% | 34 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 56 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 12 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 17 | $0.00 |
| 80202 | 0% | 25 | $0.00 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | 0% | 14 | $0.00 |
| 87899 | 0% | 16 | $0.00 | |
| 87076 | 0% | 15 | $0.00 | |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | 0% | 707 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 3,081 | $0.00 |
| 87493 | 0% | 19 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 63 | $0.00 |
| A6022 | Collagen dressing, sterile, size more than 16 sq. in. but less than or equal to 48 sq. in., each | 0% | 66 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 95 | $0.00 |
| A6214 | Foam dressing, wound cover, sterile, pad size more than 48 sq. in., with any size adhesive border, each dressing | 0% | 57 | $0.00 |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | 0% | 761 | $0.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 60 | $0.00 |
| 88341 | 0% | 145 | $0.00 | |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 173 | $0.00 |
| 36416 | 0% | 92 | $0.00 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 16 | $0.00 |
| 87449 | 0% | 66 | $0.00 | |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 41 | $0.00 |
| 73060 | 0% | 28 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 31 | $0.00 |
| A6441 | Padding bandage, non-elastic, non-woven/non-knitted, width greater than or equal to three inches and less than five inches, per yard | 0% | 25 | $0.00 |
| A6454 | Self-adherent bandage, elastic, non-knitted/non-woven, width greater than or equal to three inches and less than five inches, per yard | 0% | 26 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANCOCK, MELINDA (CFO)
Parent organizationSENTARA HEALTHCARE
| Provider | Location | Paid |
|---|---|---|
| Sentara Hospitals | Norfolk, VA | $88.20M |
| Sentara Hospitals | Hampton, VA | $78.52M |
| Potomac Hospital Corporation of Prince William | Woodbridge, VA | $59.17M |
| Sentara Hospitals | Suffolk, VA | $57.85M |
| Sentara RMH Medical Center | Harrisonburg, VA | $52.95M |
| Sentara Hospitals | Virginia Beach, VA | $52.40M |
| Sentara Princess Anne Hospital | Virginia Beach, VA | $37.50M |
| Martha Jefferson Hospital | Charlottesville, VA | $26.95M |
| Halifax Regional Hospital, INC. | South Boston, VA | $23.28M |
| Sentara Hospitals | Williamsburg, VA | $21.89M |
| Sentara Albemarle Regional Medical Center | Elizabeth City, NC | $13.82M |
| Sentara Reference Lab Solutions, LLC | Norfolk, VA | $4.74M |
| Halifax Regional Hospital, INC | South Boston, VA | $1.61M |
| Halifax Regional Hospital, INC | Nathalie, VA | $348K |
| Halifax Regional Hospital, INC | South Boston, VA | $336K |
| Halifax Regional Hospital, INC | Chase City, VA | $298K |
| Halifax Regional Hospital, INC | Clarksville, VA | $265K |
| Sentara Hospitals | Norfolk, VA | $171K |
| Halifax Regional Hospital, INC | South Boston, VA | $170K |
| Sentara Hospitals | Norfolk, VA | $128K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.